Yi Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Du has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Zehuai Wen
Guangdong Provincial Hospital of Chinese Medicine (Second Affiliated Hospital of Guangzhou University of Chinese Medicine) Guangdong Provincial Academy of Chinese Medical Sciences Guangzhou China
3 shared publications Bo Dong
The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
2 shared publicationsGeng Li
Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou
2 shared publicationsJunwen Jiang
The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
2 shared publicationsLi Zhou
Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou
2 shared publicationsShaojun Liao
The Second Clinical College of Guangzhou University of Chinese Medicine
2 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1787481
Effects of Xuefu Zhuyu oral liquid as adjunctive treatment for stable angina: a randomized controlled trial
Background: Stable angina (SA) remains a major cause of global disability. Xuefu Zhuyu oral liquid (XZOL), a traditional Chinese medicine, is used for SA in China, but rigorous evidence of its efficacy is lacking. We aimed to evaluate the efficacy and safety of XZOL as an adjunctive therapy for patients with SA. Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled trial across six hospitals in China. Between June 2020 and June 2022, eligible patients with SA were randomly assigned (1:1) to receive either XZOL or a matching placebo for 12 weeks, in addition to standard antianginal therapy. All participants were followed for an additional 12 weeks. The primary outcome was the change in average angina pain intensity from baseline to week 12, measured on a 10-cm visual analog scale (VAS). Results: Of 263 patients screened, 148 were included in the full analysis set (74 per group). At week 12, patients receiving XZOL showed a reduction in VAS pain scores compared to placebo (adjusted mean difference, –0.63; 95% CI, –1.12 to –0.14; P = 0.012). This effect was sustained at the 24-week follow-up (–0.47; 95% CI, –0.94 to –0.002; P = 0.049). Furthermore, the XZOL group had significantly lower use of rescue nitroglycerin at both week 12 (2.7% vs. 13.5%; P = 0.016) and week 24 (2.7% vs. 12.2%; P = 0.029). Adverse events were comparable between groups. Conclusion: Adjunctive treatment with XZOL for 12 weeks significantly reduced angina pain intensity and the need for rescue medication in patients with stable angina, with a favorable safety profile. Clinical trial registration: https://clinicaltrials.gov/ , ChiCTR1900026899.
- 29 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1787481
Open AccessEffects of Xuefu Zhuyu oral liquid as adjunctive treatment for stable angina: a randomized controlled trial
Background: Stable angina (SA) remains a major cause of global disability. Xuefu Zhuyu oral liquid (XZOL), a traditional Chinese medicine, is used for SA in China, but rigorous evidence of its efficacy is lacking. We aimed to evaluate the efficacy and safety of XZOL as an adjunctive therapy for patients with SA. Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled trial across six hospitals in China. Between June 2020 and June 2022, eligible patients with SA were randomly assigned (1:1) to receive either XZOL or a matching placebo for 12 weeks, in addition to standard antianginal therapy. All participants were followed for an additional 12 weeks. The primary outcome was the change in average angina pain intensity from baseline to week 12, measured on a 10-cm visual analog scale (VAS). Results: Of 263 patients screened, 148 were included in the full analysis set (74 per group). At week 12, patients receiving XZOL showed a reduction in VAS pain scores compared to placebo (adjusted mean difference, –0.63; 95% CI, –1.12 to –0.14; P = 0.012). This effect was sustained at the 24-week follow-up (–0.47; 95% CI, –0.94 to –0.002; P = 0.049). Furthermore, the XZOL group had significantly lower use of rescue nitroglycerin at both week 12 (2.7% vs. 13.5%; P = 0.016) and week 24 (2.7% vs. 12.2%; P = 0.029). Adverse events were comparable between groups. Conclusion: Adjunctive treatment with XZOL for 12 weeks significantly reduced angina pain intensity and the need for rescue medication in patients with stable angina, with a favorable safety profile. Clinical trial registration: https://clinicaltrials.gov/ , ChiCTR1900026899.
- Open Access
Xuefu Zhuyu Oral Liquid as Adjunctive Therapy on Stable Angina: A Randomized Clinical Trial
Background: Stable angina (SA) is a leading cause of disability worldwide, and there is increasing interest in nonpharmacological treatments. Xuefu Zhuyu oral liquid (XZOL) is a Chinese medicine that has been approved in China for the treatment of SA, but further studies are needed to establish its efficacy and safety. We aimed to provide a reliable assessment of the safety and efficacy of XZOL in patients with SA. Methods: We did a multi-centre, randomised, double-blind, placebo-controlled trial at 6 hospitals in China. Participants were randomized into 2 treatment groups, and allocated to receive of either XZOL or matching placebo over 12 weeks and were followed-up for 12 weeks. The primary efficacy outcome was the average pain intensity of angina, which was measured by the change from baseline to week 12 on a 10-cm visual analogue scale. Results: Of 263 patients screened, 148 participants were randomly assigned with primary outcome data in the ITT (intention-to-treat) population (74 in the XZOL group and 74 in the placebo group), and 99 participants in the PP (per-protocol) population (48 in the XZOL group and 51 in the placebo group). Mean change in VAS at week 12 were −2.27 in the XZOL group and −1.85 in the placebo group (difference - 0.52, 95% CI −0.99 to −0.05; P = 0.029) among the ITT population, and −2.54 in the XZOL group and −1.79 in the placebo group (difference −0.81, 95% CI −1.40 to −0.22; P = 0.007) among the PP population. The neutral results were shown in adjusted and sensitivity analyses. There was no significant difference in adverse events. Conclusion: This randomised, placebo-controlled, double-blind, clinical trial showed XZOL was associated with a significantly greater reduction in the levels of pain intensity of angina over 12 weeks and was superior to placebo in alleviating SA.
Open AccessXuefu Zhuyu Oral Liquid as Adjunctive Therapy on Stable Angina: A Randomized Clinical Trial
Background: Stable angina (SA) is a leading cause of disability worldwide, and there is increasing interest in nonpharmacological treatments. Xuefu Zhuyu oral liquid (XZOL) is a Chinese medicine that has been approved in China for the treatment of SA, but further studies are needed to establish its efficacy and safety. We aimed to provide a reliable assessment of the safety and efficacy of XZOL in patients with SA. Methods: We did a multi-centre, randomised, double-blind, placebo-controlled trial at 6 hospitals in China. Participants were randomized into 2 treatment groups, and allocated to receive of either XZOL or matching placebo over 12 weeks and were followed-up for 12 weeks. The primary efficacy outcome was the average pain intensity of angina, which was measured by the change from baseline to week 12 on a 10-cm visual analogue scale. Results: Of 263 patients screened, 148 participants were randomly assigned with primary outcome data in the ITT (intention-to-treat) population (74 in the XZOL group and 74 in the placebo group), and 99 participants in the PP (per-protocol) population (48 in the XZOL group and 51 in the placebo group). Mean change in VAS at week 12 were −2.27 in the XZOL group and −1.85 in the placebo group (difference - 0.52, 95% CI −0.99 to −0.05; P = 0.029) among the ITT population, and −2.54 in the XZOL group and −1.79 in the placebo group (difference −0.81, 95% CI −1.40 to −0.22; P = 0.007) among the PP population. The neutral results were shown in adjusted and sensitivity analyses. There was no significant difference in adverse events. Conclusion: This randomised, placebo-controlled, double-blind, clinical trial showed XZOL was associated with a significantly greater reduction in the levels of pain intensity of angina over 12 weeks and was superior to placebo in alleviating SA.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 7612721
Chinese Herbal Formula Xuefu Zhuyu for Stable Angina (CheruSA): Study Protocol for a Multicenter Randomized Controlled Trial
Introduction. Stable angina (SA) in coronary heart disease is a common ischemic heart disease endangering the patient’s quality of life and longevity. Clinical trials have demonstrated that the Chinese herbal formula Xuefu Zhuyu (XFZY) has benefits for SA patients. However, there remains a lack of high‐quality evidence to support clinical decision‐making. Therefore, we designed a randomized controlled trial (RCT) to evaluate the efficacy and safety of XFZY for SA. Methods and Analysis. This multicenter, double‐blinded RCT will be conducted in China. 152 eligible participants will be randomly assigned to either an XFZY group or a control group at a 1 : 1 ratio. Participants in the XFZY group will receive XFZY plus routine care, while those in the control group will receive placebo plus routine care. The study period is 26 weeks, including a 2‐week run‐in period, a 12‐week treatment period, and a 12‐week follow‐up. The primary outcome is the change in visual analogue scale score for angina pain intensity from baseline to 12 weeks. The secondary outcomes are the angina attack frequency and duration, the nitroglycerin dosage consumed, the Canadian Cardiovascular Society grading of effort angina, the Seattle Angina Questionnaire, the EuroQol‐5‐Dimensions‐5‐Level, the incidence of major adverse cardiac events, health cost evaluation, and overall assessment for study drugs. Ethics and Dissemination. The study has been approved by the ethics committee of Guangdong Provincial Hospital of Chinese Medicine (approval no. BF2019‐175‐01). Results will be submitted for publication in peer‐reviewed journals and disseminated at scientific conferences. This trial is registered with ChiCTR1900026899, registered on 26 October 2019.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 7612721
Open AccessChinese Herbal Formula Xuefu Zhuyu for Stable Angina (CheruSA): Study Protocol for a Multicenter Randomized Controlled Trial
Introduction. Stable angina (SA) in coronary heart disease is a common ischemic heart disease endangering the patient’s quality of life and longevity. Clinical trials have demonstrated that the Chinese herbal formula Xuefu Zhuyu (XFZY) has benefits for SA patients. However, there remains a lack of high‐quality evidence to support clinical decision‐making. Therefore, we designed a randomized controlled trial (RCT) to evaluate the efficacy and safety of XFZY for SA. Methods and Analysis. This multicenter, double‐blinded RCT will be conducted in China. 152 eligible participants will be randomly assigned to either an XFZY group or a control group at a 1 : 1 ratio. Participants in the XFZY group will receive XFZY plus routine care, while those in the control group will receive placebo plus routine care. The study period is 26 weeks, including a 2‐week run‐in period, a 12‐week treatment period, and a 12‐week follow‐up. The primary outcome is the change in visual analogue scale score for angina pain intensity from baseline to 12 weeks. The secondary outcomes are the angina attack frequency and duration, the nitroglycerin dosage consumed, the Canadian Cardiovascular Society grading of effort angina, the Seattle Angina Questionnaire, the EuroQol‐5‐Dimensions‐5‐Level, the incidence of major adverse cardiac events, health cost evaluation, and overall assessment for study drugs. Ethics and Dissemination. The study has been approved by the ethics committee of Guangdong Provincial Hospital of Chinese Medicine (approval no. BF2019‐175‐01). Results will be submitted for publication in peer‐reviewed journals and disseminated at scientific conferences. This trial is registered with ChiCTR1900026899, registered on 26 October 2019.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 7504917
Brain Functional Differences in Drug‐Naive Major Depression with Anxiety Patients of Different Traditional Chinese Medicine Syndrome Patterns: A Resting‐State fMRI Study
Major depressive disorder (MDD), especially combined with anxiety, has a high incidence and low detection rate in China. Literature has shown that patients under major depression with anxiety (MDA) are more likely to nominate a somatic, rather than psychological, symptom as their presenting complaint. In the theory of Traditional Chinese Medicine (TCM), clinical symptoms of MDD patients are mainly categorized into two different syndrome patterns: Deficiency and Excess. We intend to use resting‐state functional magnetic resonance imaging (rs‐fMRI) to investigate their brain functional differences and hopefully to find their brain function mechanism. For our research, 42 drug‐naive MDA patients were divided into two groups (21 for Deficiency and 21 for Excess), with an additional 19 unaffected participants in the normal control (NC) group. We took Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Scale (HAMA), and brain fMRI scan for each group and analyzed the data. We first used Degree Centrality (DC) to map the functional differences in brain regions, utilized these regions as seed points, and used a seed‐based functional connectivity (FC) analysis to identify the specific functional connection between groups. The Deficiency group was found to have higher HAMD scores, HAMA scores, and HAMD somatic factor than the Excess group. In the DC analysis, significant decreases were found in the right precuneus of both the Deficiency and Excess groups compared to the NC group. In the FC analysis, the right precuneus showed significant decreased network connectivity with the bilateral cuneus, as well as the right lingual gyrus in the Deficiency group when compared to the NC group and the Excess group. Through our research, it was found that precuneus dysfunction may have a relationship with MDA and Deficiency patients have more severe physical and emotional symptoms, and we realized that a larger sample size and multiple brain mode observations were needed in further research.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 7504917
Open AccessBrain Functional Differences in Drug‐Naive Major Depression with Anxiety Patients of Different Traditional Chinese Medicine Syndrome Patterns: A Resting‐State fMRI Study
Major depressive disorder (MDD), especially combined with anxiety, has a high incidence and low detection rate in China. Literature has shown that patients under major depression with anxiety (MDA) are more likely to nominate a somatic, rather than psychological, symptom as their presenting complaint. In the theory of Traditional Chinese Medicine (TCM), clinical symptoms of MDD patients are mainly categorized into two different syndrome patterns: Deficiency and Excess. We intend to use resting‐state functional magnetic resonance imaging (rs‐fMRI) to investigate their brain functional differences and hopefully to find their brain function mechanism. For our research, 42 drug‐naive MDA patients were divided into two groups (21 for Deficiency and 21 for Excess), with an additional 19 unaffected participants in the normal control (NC) group. We took Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Scale (HAMA), and brain fMRI scan for each group and analyzed the data. We first used Degree Centrality (DC) to map the functional differences in brain regions, utilized these regions as seed points, and used a seed‐based functional connectivity (FC) analysis to identify the specific functional connection between groups. The Deficiency group was found to have higher HAMD scores, HAMA scores, and HAMD somatic factor than the Excess group. In the DC analysis, significant decreases were found in the right precuneus of both the Deficiency and Excess groups compared to the NC group. In the FC analysis, the right precuneus showed significant decreased network connectivity with the bilateral cuneus, as well as the right lingual gyrus in the Deficiency group when compared to the NC group and the Excess group. Through our research, it was found that precuneus dysfunction may have a relationship with MDA and Deficiency patients have more severe physical and emotional symptoms, and we realized that a larger sample size and multiple brain mode observations were needed in further research.
- Open Access
- 30 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 422
Traditional Chinese medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial
Stable angina pectoris is experienced as trans-sternal or retro-sternal pressure or pain that may radiate to the left arm, neck or back. Although available evidence relating to its effectiveness and mechanism are weak, traditional Chinese medicine is used as an alternative therapy for stable angina pectoris. We report a protocol of a randomized controlled trial using traditional Chinese medicine to investigate the effectiveness, mechanism and safety for patients with stable angina pectoris. This is a north-east Chinese, multi-center, multi-blinded, placebo-controlled and superiority randomized trail. A total of 240 patients with stable angina pectoris will be randomly assigned to three groups: two treatment groups and a control group. The treatment groups will receive Chinese herbal medicine consisting of Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo granule and Yi-Qi-Jian-Pi and Qu-Tan-Hua-Yu granule, respectively, and conventional medicine. The control group will receive placebo medicine in addition to conventional medicine. All 3 groups will undergo a 12-week treatment and 2-week follow-up. Four visits in sum will be scheduled for each subject: 1 visit each in week 0, week 4, week 12 and week 14. The primary outcomes include: the frequency of angina pectoris attack; the dosage of nitroglycerin; body limited dimension of Seattle Angina Questionnaire. The secondary outcomes include: except for the body limited dimension of SAQ, traditional Chinese medicine pattern questionnaire and so on. Therapeutic mechanism outcomes, safety outcomes and endpoint outcomes will be also assessed. The primary aim of this trial is to develop a standard protocol to utilize high-quality EBM evidence for assessing the effectiveness and safety of SAP via TCM pattern differentiation as well as exploring the efficacy mechanism and regulation with the molecular biology and systems biology. Clinical Trials Registration: ChiCTR-TRC-13003608 , registered 18 June 2013.
- 30 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 422
Open AccessTraditional Chinese medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial
Stable angina pectoris is experienced as trans-sternal or retro-sternal pressure or pain that may radiate to the left arm, neck or back. Although available evidence relating to its effectiveness and mechanism are weak, traditional Chinese medicine is used as an alternative therapy for stable angina pectoris. We report a protocol of a randomized controlled trial using traditional Chinese medicine to investigate the effectiveness, mechanism and safety for patients with stable angina pectoris. This is a north-east Chinese, multi-center, multi-blinded, placebo-controlled and superiority randomized trail. A total of 240 patients with stable angina pectoris will be randomly assigned to three groups: two treatment groups and a control group. The treatment groups will receive Chinese herbal medicine consisting of Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo granule and Yi-Qi-Jian-Pi and Qu-Tan-Hua-Yu granule, respectively, and conventional medicine. The control group will receive placebo medicine in addition to conventional medicine. All 3 groups will undergo a 12-week treatment and 2-week follow-up. Four visits in sum will be scheduled for each subject: 1 visit each in week 0, week 4, week 12 and week 14. The primary outcomes include: the frequency of angina pectoris attack; the dosage of nitroglycerin; body limited dimension of Seattle Angina Questionnaire. The secondary outcomes include: except for the body limited dimension of SAQ, traditional Chinese medicine pattern questionnaire and so on. Therapeutic mechanism outcomes, safety outcomes and endpoint outcomes will be also assessed. The primary aim of this trial is to develop a standard protocol to utilize high-quality EBM evidence for assessing the effectiveness and safety of SAP via TCM pattern differentiation as well as exploring the efficacy mechanism and regulation with the molecular biology and systems biology. Clinical Trials Registration: ChiCTR-TRC-13003608 , registered 18 June 2013.